Drug shortage
Tirzepatide Injection · Eli Lilly and Co.
FDA drug shortage · Resolved · updated Dec 19, 2024
Key facts
| Generic name | Tirzepatide Injection |
|---|---|
| Proprietary name | Zepbound |
| Company | Eli Lilly and Co. |
| Presentation | Zepbound, Injection, 12.5 mg/.5 mL (NDC 0002-2460-80) |
| Dosage form | Injection |
| Strength | 12.5 mg/.5 mL |
| Status | Resolved |
| Therapeutic category | Endocrinology/Metabolism |
| Package NDCs | 0002-2460-80 |
| First posted | Dec 15, 2022 |
| Last updated | Dec 19, 2024 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: